Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

News

Immunovia’s new share issue subscribed to a value of SEK 305 million

19 November 2015

The rights issue of Immunovia AB (publ) (“Immunovia” or ” the Company”) for the Company’s listing on Nasdaq First North was subscribed to SEK 305 million, which corresponds to a subscription ratio of approximately 500 percent.

Read More

Vator Securities successfully completes advisory mission for Vikingaliv

11 June 2015

Vator Securities acted as exclusive financial advisor for Vikingaliv and assisted with obtaining both bank financing and share capital.

Read More

Vator Securities successfully completes advisory mission for Immunovia

20 May 2015

Immunovia AB is a Swedish molecular diagnostics company that has developed what can become the world’s first robust test for early diagnosis of pancreatic cancer, which is the fourth deadliest cancer form in the world.

Read More

Vator Securities successfully completes advisory mission for IRRAS

24 March 2015

IRRAS has developed a unique pump and catheter system for efficient drainage of fluids from the body and for local administration of drugs in the body.

Read More

Vator Securities successfully completes advisory mission for Bio-Works Technologies

18 December 2014

Bio-Works is a biotechnology company that develops, produces and sells innovative separation media products based on agarose to purify proteins, peptides and other biomolecules.

Read More